Periodic Reporting for period 1 - I3LUNG (Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy)

Although immunotherapy is the new standard of care for advanced non-small cell lung cancer (NSCLC), less than 50 % of patients benefit from this treatment in the long term. Programmed death-ligand 1 biomarker is used to predict immunotherapy outcomes with limited efficacy, and...